PET/CT in the evaluation of patients with squamous cell cancer of the head and neck

Goshen, E.; Davidson, T.; Yahalom, R.; Talmi, Y.P.; Zwas, S.T.

doi:10.1016/j.ijom.2005.08.003

« Previous Next »International Journal of Oral & Maxillofacial Surgery
Volume 35, Issue 4 , Pages 332-336, April 2006

PET/CT in the evaluation of patients with squamous cell cancer of the head and neck

E. Goshen
- Department of Nuclear Medicine, The Chaim Sheba Medical Center, Tel Hashomer, and Sackler School of Medicine, Tel Aviv University, Israel
- Address: Elinor Goshen, Department of Nuclear Medicine, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel. Tel: +972 3 5302524; Fax: +972 3 5302075.
T. Davidson
- Department of Nuclear Medicine, The Chaim Sheba Medical Center, Tel Hashomer, and Sackler School of Medicine, Tel Aviv University, Israel
R. Yahalom
- Department of Oral and Maxillofacial Surgery, The Chaim Sheba Medical Center, Tel Hashomer, and Sackler School of Medicine, Tel Aviv University, Israel
Y.P. Talmi
- Department of Otolaryngology-Head and Neck Surgery, The Chaim Sheba Medical Center, Tel Hashomer, and Sackler School of Medicine, Tel Aviv University, Israel
S.T. Zwas
- Department of Nuclear Medicine, The Chaim Sheba Medical Center, Tel Hashomer, and Sackler School of Medicine, Tel Aviv University, Israel

Accepted 3 August 2005.

Abstract

The purpose of this study was to compare the findings of positron emission tomography (PET) with fused PET and computed tomography (CT) in patients with suspected locoregional and distant head and neck cancer and to evaluate the impact of those findings on clinical management.

Studies of 25 patients were retrospectively evaluated. PET findings were classified as malignant, benign or equivocal. PET/CT findings were then similarly classified and the PET-only results were amended accordingly. Comparison of findings was done on lesion and patient levels. A total of 45 foci of increased 18F-fluorodeoxyglucose (FDG) uptake were noted in 18 patients. PET/CT imaging defined anatomic localization of 41/45 lesions and clarified 6/10 equivocal PET findings. Additional information was provided by PET/CT regarding 9/45 (20%) of the lesions. PET/CT significantly affected patient management in 3/25 patients (12%) by limiting the extent of disease in one and excluding viable disease in two others. The accuracy of PET/CT was 88%, the sensitivity 100% and the specificity was 77%. The negative predictive value was 100% in this combined group of patients with locoregional and distant head and neck cancer.

PET/CT is highly contributory for initial staging and in the evaluation of patients with suspected recurrent SCC of the head and neck, in whom anatomic imaging is inconclusive due to the locoregional distortions rendered by surgery and radiotherapy.

Key words: PET/CT, head and neck, squamous cell carcinoma